ESSA Pharma Inc.根據不列顛哥倫比亞省法律於2009年1月6日註冊成立。該公司是一家處於發展階段的製藥公司,專註於小分子藥物的開發以治療閹割性前列腺癌(“CRPC”)。該公司正在開發的藥物是選擇性阻斷雄激素受體(“AR”)的氨基末端結構域(“NTD”),能夠潛在地克服CRPC的已知AR - 依賴性機制,從而使CRPC患者病情不惡化,提高生存率。
董事
名稱
職位
David Parkinson
President, Chief Executive Officer and Director
Richard M. Glickman
Chairman of the Board
Alex Martin
Director
Franklin Berger
Director
Gary Sollis
Director
Lauren Merendino
Director
Marella Thorell
Director
Philip Kantoff
Director
Sanford Zweifach
Director
Scott Requadt
Director
股東
名稱
職位
David Parkinson
President, Chief Executive Officer and Director
Peter Virsik
Executive Vice President and Chief Operating Officer